In the context of translational regenerative medicine, biomarkers not only characterize the function, quality, and safety/toxicity of a product (potency) but also help identify those patients or cohorts who would most likely benefit from such an innovative treatment modality (prediction or stratification) and allow efficacy in those patients who have been identified as responders to be monitored.
The small number of patients with non-clear-cell histotypes did not allow efficacy evaluations in these less frequent histologies.
These strategies allow efficacy to be determined in a preliminary fashion with a fraction of the subjects, cost, and time of a cancer incidence trial.
For example, modeling allows efficacy across doses to be shown without the need for costly additional clinical trials, allows exploration of relationships between patient characteristics and PK parameters, and enables assessment of exposure and response in the target population.
This study was designed as a treat-to-target trial to allow efficacy and safety comparisons of the new basal insulin degludec with the most frequently prescribed basal insulin, glargine.
Moreover, such a meta-analysis will allow efficacy and safety/tolerability ranking of medications by taking advantage of the measured differences versus common comparators, even if the medications are not or only insufficiently compared head to head.
The authors examined data from the Corticosteroid Randomization After Significant Head Injury (CRASH) trial [ 2, 3] to illustrate how alternative methodological and statistical analyses increase statistical power, reduce sample size requirements, and allow efficacy to be detected.
The placebo was described as a scientific tool that would allow efficacy of the target treatment to be determined; the target treatment was described as a treatment that might generate health effects.
A case is presented in which this system allowed considerable efficacy in reaching a solution.
To assess the impact of targeted vaccination, we used a time-usage study's mixing matrix and allowed vaccine efficacy to vary with age.
